↓ Skip to main content

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis

Overview of attention for article published in Multiple Sclerosis and Related Disorders, January 2022
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
20 X users

Citations

dimensions_citation
18 Dimensions

Readers on

mendeley
49 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
Published in
Multiple Sclerosis and Related Disorders, January 2022
DOI 10.1016/j.msard.2021.103448
Pubmed ID
Authors

David Baker, Amy MacDougall, Angray S. Kang, Klaus Schmierer, Gavin Giovannoni, Ruth Dobson

X Demographics

X Demographics

The data shown below were collected from the profiles of 20 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 49 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 12%
Student > Bachelor 5 10%
Other 4 8%
Student > Doctoral Student 4 8%
Student > Ph. D. Student 3 6%
Other 6 12%
Unknown 21 43%
Readers by discipline Count As %
Medicine and Dentistry 8 16%
Neuroscience 4 8%
Unspecified 3 6%
Biochemistry, Genetics and Molecular Biology 3 6%
Agricultural and Biological Sciences 3 6%
Other 9 18%
Unknown 19 39%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 November 2022.
All research outputs
#1,357,774
of 24,575,707 outputs
Outputs from Multiple Sclerosis and Related Disorders
#96
of 2,985 outputs
Outputs of similar age
#33,637
of 511,978 outputs
Outputs of similar age from Multiple Sclerosis and Related Disorders
#5
of 150 outputs
Altmetric has tracked 24,575,707 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,985 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 511,978 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 150 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.